drugset / Trial / NCT04313868
GEN2 Directed Cancer Immunotherapy Trial
Non-randomizedParallel-groupOpen-labelOther
Summary
Phase 1, non-randomized, open label dose escalation clinical trial evaluating the safety of GEN2 in participants with primary \& metastatic liver tumors.
Timeline
- Start
- 2014-06-13
- Primary completion
- 2023-12-12
- Completion
- 2023-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GEN2 | Gene therapy (AAV / viral vector) | — | Intravenous |